Bank of New York Mellon Corp decreased its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 2.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,444,720 shares of the specialty pharmaceutical company’s stock after selling 39,379 shares during the period. Bank of New York Mellon Corp owned 2.77% of Supernus Pharmaceuticals worth $86,466,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. California Public Employees Retirement System lifted its holdings in Supernus Pharmaceuticals by 39.4% during the 2nd quarter. California Public Employees Retirement System now owns 72,557 shares of the specialty pharmaceutical company’s stock worth $4,343,000 after buying an additional 20,496 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in Supernus Pharmaceuticals by 3.2% during the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after buying an additional 20,012 shares in the last quarter. Castleark Management LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $18,065,000. Kopp Investment Advisors LLC lifted its holdings in Supernus Pharmaceuticals by 13.3% during the 2nd quarter. Kopp Investment Advisors LLC now owns 41,879 shares of the specialty pharmaceutical company’s stock worth $2,506,000 after buying an additional 4,903 shares in the last quarter. Finally, Putnam Investments LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $1,069,000. 99.10% of the stock is owned by institutional investors and hedge funds.

A number of research firms have issued reports on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday. Cantor Fitzgerald set a $57.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. BidaskClub lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. Finally, Mizuho began coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They set a “buy” rating and a $61.00 target price on the stock. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $54.78.

Shares of SUPN opened at $45.27 on Friday. Supernus Pharmaceuticals Inc has a twelve month low of $34.90 and a twelve month high of $61.25. The firm has a market capitalization of $2.36 billion, a PE ratio of 35.93 and a beta of 0.92. The company has a current ratio of 2.82, a quick ratio of 2.54 and a debt-to-equity ratio of 0.77.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The business had revenue of $102.99 million for the quarter, compared to analyst estimates of $100.75 million. During the same period last year, the business earned $0.29 EPS. The company’s revenue was up 28.1% on a year-over-year basis. Equities analysts expect that Supernus Pharmaceuticals Inc will post 1.88 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Has $86.47 Million Stake in Supernus Pharmaceuticals Inc (SUPN)” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2018/11/11/bank-of-new-york-mellon-corp-has-86-47-million-stake-in-supernus-pharmaceuticals-inc-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: Cost of Capital Explained

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.